Simvastatin decreases aldehyde production derived from lipoprotein oxidation

American Journal of Cardiology

Volumn 83, Issue 6, 1999, Pages 846-851

  Girona, Josefa ^a   La Ville, Agnes E ^a   Solà, Rosa ^a   Plana, Núria ^a   Masana, Lluís ^a  

^a Unitat d'Investigacio l'Hosp S   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL;

ALDEHYDES; ANTILIPEMIC AGENTS; ANTIOXIDANTS; HUMANS; HYPERLIPIDEMIAS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; SIMVASTATIN; VITAMIN E;

EID: 0033002575     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)01071-6     Document Type: Article

References (29)

1. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 333:1995;1301-1307.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
4. Keidar S., Aviram M., Maor I., Brook J.G. Pravastatin inhibits cellular cholesterol syntesis and increases low density lipoprotein receptor activity in macrophages in vitro and in vivo studies . Br J Clin Pharmacol. 38:1994;513-519.
5. Rogler G., Lackner K.J., Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol. 76:1995;114A-116A.
6. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou T., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation. 89:1994;2519-2524.
7. Mayer J., Eller T., Brauer P. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 64:1992;196-201.
8. Lacoste L., Lam J.Y.T., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidaemia and coronary disease corection of the increased thrombogenic potential with cholesterol reduction . Circulation. 92:1995;3172-3177.
9. Steinberg D., Lewis A. Conner memorial lecture. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
10. Liu Y., Hultén L.M., Wiklund. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol. 17:1997;317-323.
11. Brown M.S., Dana S.E., Goldstein J.C. Cholesterol ester formation in cultured human fibroblasts, stimulation by oxygenated sterols. J Biol Chem. 250:1975;4025-4027.
12. Girona J., La Ville A.E., Heras M., Olivé S., Masana L. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-α secretion by THP-1 human macrophages. Free Rad Bio Med. 23:1997;658-667.
13. Fong L.G., Fong T.A.T., Cooper A.D. Inhibition of lipopolysaccharide-induced interleukin-1β mRNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res. 32:1991;1899-1910.
14. Steinbrecher U.P., Lougheed M., Kwan W.C., Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein by-probucts of fatty acid peroxidation. J Biol Chem. 264:1989;15216-15223.
15. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
16. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol. 128:1986;155-170.
17. Kleinveld H.A., Hak-Lemmers H.L.M., Stalenhoef A.F.H., Demacker P.N.M. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation application of a short procedure for isolating low-density lipoprotein . Clin Chem. 38:1992;2066-2072.
18. Lowry O.H., Rosebrough N.J., Farr N.J., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
19. Catignani G.L., Bieri J.G. Simultaneous determination of retinol and α-tocopherol in serum or plasma by liquid chromatography. Clin Chem. 29:1983;708-712.
20. Esterbauer H., Cheeseman H. Determination of aldehydic lipid peroxidation products malonaldehyde and 4-hydroxynonenal . Methods Enzymol. 182:1990;407-421.
21. La Ville A.E., Solà R., Balanyà J., Turner P.R., Masana L. In vitro oxidized HDL is recognised by the scavenger receptor of macrophages implications for its protective role in vivo . Atherosclerosis. 105:1994;179-189.
22. Yoshida H., Ishikawa T., Ayaori M., Shige H., Hosoai H., Nishio E., Tomiyasu T., Suzukawa M., Nishiwaki M., Ikewaki K., Nakamura H. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia a pilot study . Clin Ther. 17:1995;379-389.
23. Kleinveld H.A., Demacker P.N.M., de Haan A.F.J., Stalenhoef A.F.H. Decreased in vitro oxidizability of low density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest. 23:1993;289-295.
24. Bredie S.J.H., de Bruin T.W.A., Demaker P.N.M., Kastelein J.J.P., Stalenhoef A.F.H. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 75:1995;348-353.
25. Jialal I., Fuller C.J., Huet B.A. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol. 15:1995;190-198.
26. Esterbauer H., Ramos P. Chemistry and pathophisiology of oxidation of LDL. Rev Physiol Biochem Pharmacol. 127:1995;31-64.
27. Kaneko T., Kaji K., Matsuo M. Cytotoxicities of a linoleic acid hydroperoxide and its related aliphatic aldehydes toward cultured human umbilical endothelial cells. Chem Biol Interactions. 67:1988;295-304.
28. Giroux L.M., Davignon J., Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1165:1993;335-338.
29. Aviram M., Dankner G., Cogan U., Hochgraf E., Brook J.G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages in vitro and in vivo studies . Metabolism. 41:1992;229-235.